drugset
Drugs / Sintilimab
last change 3 days ago re-read 9 days ago

Sintilimab

also known as IBI308 · Sintilimab Injection · Tyvyt · Darbersol · Sin · Sindilizumab · Sintilimab (IBI308) · Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel

Monoclonal antibody targets PDCD1 via inhibition

Developed for
hepatocellular carcinoma · non-small cell lung carcinoma · gastric cancer · colorectal cancer · esophageal squamous cell carcinoma · cancer · gastroesophageal adenocarcinoma · gastroesophageal junction adenocarcinoma
+109 more · rectal cancer · nasopharyngeal carcinoma · head and neck squamous cell carcinoma · extranodal nasal NK/T cell lymphoma · gastric adenocarcinoma · lung cancer · small cell lung carcinoma · intrahepatic cholangiocarcinoma · malignant pancreatic neoplasm · metastasis from malignant tumor of colon · biliary tract cancer · diffuse large B-cell lymphoma · oral cavity squamous cell carcinoma · renal cell carcinoma · triple-negative breast carcinoma · cervical cancer · endometrial cancer · esophageal cancer · gastric neoplasm · neoplasm · rectum adenocarcinoma · chronic hepatitis B virus infection · colorectal carcinoma · metastatic malignant neoplasm · neuroendocrine carcinoma · non-small cell squamous lung carcinoma · portal vein thrombosis · soft tissue sarcoma · adenocarcinoma · anal squamous cell carcinoma · breast cancer · cancer of unknown primary site · classic Hodgkin lymphoma · colon carcinoma · colorectal adenocarcinoma · glioblastoma · lung carcinoma · mature T-cell and NK-cell non-Hodgkin lymphoma · metastatic neoplasm · oropharynx squamous cell carcinoma · primary central nervous system lymphoma · cervical carcinoma · childhood malignant neoplasm · cholangiocarcinoma · gastric carcinoma · gastroesophageal cancer · metastatic malignant neoplasm in the brain · nasopharyngeal neoplasm · neoplastic disease or syndrome · neuroblastoma · peripheral T-cell lymphoma, not otherwise specified · peritoneal carcinomatosis · primary cutaneous T-cell lymphoma · rectal carcinoma · acral lentiginous melanoma · AIDS · anal canal cancer · angioimmunoblastic T-cell lymphoma · angiosarcoma · appendix carcinoma · carcinoma · carcinoma of esophagus · central nervous system non-hodgkin lymphoma · clear cell renal carcinoma · colonic neoplasm · colorectal neoplasm · combined hepatocellular carcinoma and cholangiocarcinoma · cutaneous melanoma · digestive system cancer · digestive system neoplasm · endometrioid adenocarcinoma · endometrium adenocarcinoma · Epstein-Barr virus infection · exocrine pancreatic carcinoma · follicular lymphoma · gallbladder cancer · hemophagocytic syndrome · hepatoblastoma · hepatoid adenocarcinoma · inborn disorder of energy metabolism · liver cancer · lung neoplasm · lymphoepithelioma-like lung carcinoma · malignant epithelial tumor of salivary glands · malignant leptomeningeal tumor · malignant peritoneal mesothelioma · malignant pleural mesothelioma · mantle cell lymphoma · meningioma · mucosal melanoma · nasal cavity and paranasal sinus carcinoma · neuroendocrine neoplasm · oral cavity cancer · ovarian cancer · ovarian clear cell adenocarcinoma · ovarian clear cell cancer · pancreas disorder · pancreatic exocrine neoplasm · peritoneal neoplasm · primary mediastinal large B-cell lymphoma · small intestine adenocarcinoma · thoracic cancer · thyroid cancer · thyroid tumor · transitional cell neoplasm · tumor of salivary gland · undifferentiated pleomorphic sarcoma · Hodgkins lymphoma · peritoneal mesothelioma
Investigated by
Innovent Biologics (Suzhou) Co. Ltd. · Sun Yat-sen University · Fudan University · Tianjin Medical University Cancer Institute and Hospital · Zhejiang Cancer Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
+293 more · The First Affiliated Hospital with Nanjing Medical University · Second Affiliated Hospital, School of Medicine, Zhejiang University · West China Hospital · Second Affiliated Hospital of Guangzhou Medical University · Tongji Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Zhejiang University · Henan Cancer Hospital · Peking Union Medical College Hospital · Shanghai Zhongshan Hospital · Chinese PLA General Hospital · Fujian Cancer Hospital · Ruijin Hospital · Sichuan University · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · The First Hospital of Jilin University · Guangdong Provincial People's Hospital · Nanfang Hospital, Southern Medical University · RenJi Hospital · The First Affiliated Hospital of Zhengzhou University · Chinese Academy of Medical Sciences · Hebei Medical University Fourth Hospital · Qilu Hospital of Shandong University · Shandong Cancer Hospital and Institute · Shanghai Chest Hospital · Xin-Hua Xu · Beijing 302 Hospital · Hunan Province Tumor Hospital · Innovent Biologics, Inc. · Peking University · Peking University Cancer Hospital & Institute · Peking University People's Hospital · Sichuan Cancer Hospital and Research Institute · Sixth Affiliated Hospital, Sun Yat-sen University · Tang-Du Hospital · Xiangya Hospital of Central South University · Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Anhui Provincial Cancer Hospital · Beijing Friendship Hospital · Beijing Tongren Hospital · China Medical University, China · Chongqing Three Gorges Central Hospital · Fifth Affiliated Hospital, Sun Yat-Sen University · First Affiliated Hospital of Chongqing Medical University · First Affiliated Hospital of Zhejiang University · First Affiliated Hospital, Sun Yat-Sen University · First People's Hospital of Foshan · Guangdong Association of Clinical Trials · Hangzhou Neoantigen Therapeutics Co., Ltd. · Hubei Cancer Hospital · Hutchmed · M.D. Anderson Cancer Center · Shanghai Changzheng Hospital · Shanghai Pulmonary Hospital, Shanghai, China · Shengjing Hospital · Sun Yat-sen University Cancer Center · The Affiliated Hospital Of Southwest Medical University · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · The First Affiliated Hospital of Soochow University · The First Affiliated Hospital of Xiamen University · Third Affiliated Hospital, Sun Yat-Sen University · Affiliated Hospital of Guangdong Medical University · Aiping Zhou · Beijing Bethune Charitable Foundation · Beijing Hospital · Beijing Tsinghua Chang Gung Hospital · Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Eastern Hepatobiliary Surgery Hospital · First Affiliated Hospital Xi'an Jiaotong University · First Affiliated Hospital of Fujian Medical University · First Affiliated Hospital of Guangxi Medical University · First Affiliated Hospital of Wannan Medical College · GeneCast Biotechnology Co., Ltd. · all 299 on the full record

Trials 569 · started per year

today
1
4
14
60
54
93
75
58
88
58
64
201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 03 trials
Phase 0 NCT06497010 Aug 2024 → Jul 2026 overdue neoplasm The Affiliated Hospital Of Guizhou Medical University Recruiting No outcome recorded
Phase 0 NCT04412408 Sep 2020 → Dec 2022 neuroblastoma Shanghai Children's Medical Center Unknown No outcome recorded
Phase 0 NCT03940001 May 2019 → May 2021 esophageal squamous cell carcinoma Zhejiang Cancer Hospital Unknown No outcome recorded
Phase 139 trials
Phase 1 NCT07457281 Apr 2026 → Apr 2027 expected head and neck squamous cell carcinoma West China Hospital Recruiting No outcome recorded
Phase 1 NCT07455617 Mar 2026 → Jun 2029 expected metastatic neoplasm Suzhou Abogen Biosciences Co., Ltd. Recruiting No outcome recorded
Phase 1 NCT07411781 Mar 2026 → Mar 2027 expected colorectal cancer Chinese PLA General Hospital Not yet recruiting No outcome recorded
Phase 1 NCT06793956 Feb 2025 → Jan 2026 overdue extranodal nasal NK/T cell lymphoma Sun Yat-sen University Recruiting No outcome recorded
Phase 1 NCT06431685 Apr 2024 → Mar 2025 overdue malignant leptomeningeal tumor, non-small cell lung carcinoma Sichuan University Recruiting No outcome recorded
Phase 1 NCT05718219 Mar 2023 → Dec 2025 overdue neoplasm Jiangsu Simcere Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded
Phase 1 NCT05427487 Feb 2023 → Jun 2028 expected colorectal cancer, gastric cancer, ovarian cancer ImmVirx Pty Ltd Recruiting No outcome recorded
Phase 1 NCT05225116 Jan 2023 → Dec 2025 hepatocellular carcinoma Beijing Tsinghua Chang Gung Hospital Unknown No outcome recorded
Phase 1 NCT05504278 Sep 2022 → May 2025 overdue non-small cell lung carcinoma Innovent Biologics (Suzhou) Co. Ltd. Recruiting No outcome recorded
Phase 1 NCT05245916 Apr 2022 → Aug 2023 cancer Innovent Biologics (Suzhou) Co. Ltd. Withdrawn No outcome recorded Stop: Business
Phase 1/243 trials
Phase 1/2 NCT07714317 Jul 2026 → Jul 2027 expected hepatocellular carcinoma Shanghai Zhongshan Hospital Not yet recruiting No outcome recorded
Phase 1/2 NCT07612137 Jun 2026 → Jun 2027 expected cancer Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT07579247 May 2026 → Dec 2029 expected AIDS Shanghai Public Health Clinical Center Not yet recruiting No outcome recorded
Phase 1/2 NCT07522411 Apr 2026 → Dec 2027 expected hepatocellular carcinoma BinYong Liang Not yet recruiting No outcome recorded
Phase 1/2 NCT07131202 Jan → Dec 2026 expected cancer Suzhou Forlong Biotechnology Co., Ltd Recruiting No outcome recorded
Phase 1/2 NCT07190027 Nov 2025 overdue non-small cell lung carcinoma First Affiliated Hospital of Wenzhou Medical University Not yet recruiting No outcome recorded
Phase 1/2 NCT06995105 Apr 2025 → Apr 2027 expected hepatocellular carcinoma Zhejiang University Recruiting No outcome recorded
Phase 1/2 NCT06956716 Apr 2025 → Apr 2027 expected intrahepatic cholangiocarcinoma Zhejiang University Recruiting No outcome recorded
Phase 1/2 NCT06888674 Apr 2025 → Apr 2027 expected pancreas disorder Zhejiang University Not yet recruiting No outcome recorded
Phase 1/2 NCT06742411 Dec 2024 → Dec 2026 expected gastric cancer West China Hospital Recruiting No outcome recorded
Phase 2390 trials · 10 met primary · 2 missed
Phase 2 NCT07819019 Oct 2026 → Oct 2028 expected gastric cancer Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center Not yet recruiting No outcome recorded
Phase 2 NCT07799077 Sep 2026 → Dec 2027 expected esophageal squamous cell carcinoma Hebei Medical University Fourth Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07602140 Aug 2026 → Aug 2028 expected gastric cancer Shandong Provincial Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07715565 Aug 2026 → Dec 2029 expected renal cell carcinoma West China Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07645846 Jul 2026 → Aug 2028 expected nasal cavity and paranasal sinus carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 2 NCT07722754 Jul 2026 → Jul 2028 expected colorectal cancer, metastatic malignant neoplasm Guangdong Provincial People's Hospital Recruiting No outcome recorded
Phase 2 NCT07683221 Jul 2026 → Jul 2029 expected malignant pancreatic neoplasm Shandong Cancer Hospital and Institute Not yet recruiting No outcome recorded
Phase 2 NCT07656766 Jul 2026 → Sep 2027 expected colorectal cancer Peking University People's Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07669740 Jul 2026 → Jun 2027 expected gastric cancer The First Affiliated Hospital with Nanjing Medical University Not yet recruiting No outcome recorded
Phase 2 NCT07685704 Jul 2026 → Jun 2028 expected gastric cancer, gastroesophageal junction adenocarcinoma Zhifeng Zhao, PhD Not yet recruiting No outcome recorded
Show all 390 trials opens the full record — a long page
Phase 2/313 trials · 2 met primary
Phase 2/3 NCT07643623 Jun 2026 → Dec 2031 expected adenocarcinoma Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. Not yet recruiting No outcome recorded
Phase 2/3 NCT07319429 Jan 2026 → Dec 2027 expected endometrial cancer, infertility disorder Fudan University Recruiting No outcome recorded
Phase 2/3 NCT06977061 Jun 2025 → Jun 2026 overdue gastric neoplasm Queling Liu Not yet recruiting No outcome recorded
Phase 2/3 NCT06138028 Sep 2023 → Oct 2025 overdue esophageal squamous cell carcinoma Qingdao Central Hospital Recruiting No outcome recorded
Phase 2/3 NCT05522231 Oct 2022 → Jan 2025 overdue renal cell carcinoma Hutchmed Active not recruiting Met primary
Phase 2/3 NCT05484024 Aug 2022 → Jul 2028 expected rectal cancer Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded
Phase 2/3 NCT05250843 May 2022 → Dec 2023 hepatocellular carcinoma Third Affiliated Hospital, Sun Yat-Sen University Unknown No outcome recorded
Phase 2/3 NCT05322187 Apr 2022 → Sep 2023 childhood malignant neoplasm, hepatoblastoma, transitional cell neoplasm RenJi Hospital Unknown No outcome recorded
Phase 2/3 NCT05002686 Aug 2021 → Aug 2023 gastric cancer Ruijin Hospital Unknown No outcome recorded
Phase 2/3 NCT04322617 Mar 2020 → Mar 2028 expected non-small cell lung carcinoma Hunan Province Tumor Hospital Recruiting No outcome recorded
Phase 347 trials · 8 met primary
Phase 3 NCT07827872 Oct 2026 → Oct 2032 expected oral cavity squamous cell carcinoma caohaotian Not yet recruiting No outcome recorded
Phase 3 NCT07678229 Jul 2026 → Dec 2031 expected mature T-cell and NK-cell non-Hodgkin lymphoma Rong Tao Not yet recruiting No outcome recorded
Phase 3 NCT07537946 May 2026 → May 2031 expected hepatocellular carcinoma, metastatic neoplasm Tongji Hospital Not yet recruiting No outcome recorded
Phase 3 NCT07692152 Mar 2026 → Mar 2029 expected anal squamous cell carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting No outcome recorded
Phase 3 NCT07459296 Mar 2026 → Apr 2030 expected nasopharyngeal carcinoma First Affiliated Hospital of Guangxi Medical University Recruiting No outcome recorded
Phase 3 NCT07371611 Jan 2026 → Dec 2030 expected oral cavity squamous cell carcinoma Qunxing Li,MD Recruiting No outcome recorded
Phase 3 NCT07186621 Jul 2025 → Jul 2027 expected hepatocellular carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting No outcome recorded
Phase 3 NCT06794086 Apr 2025 → Jun 2026 overdue metastasis from malignant tumor of colon Jun Huang Recruiting No outcome recorded
Phase 3 NCT06791512 Jan 2025 → Dec 2030 expected colorectal adenocarcinoma Jun Huang Recruiting No outcome recorded
Phase 3 NCT06584032 Dec 2024 → Jan 2029 expected endometrial cancer Hutchmed Recruiting No outcome recorded
Phase 44 trials
Phase 4 NCT07010393 Jul 2025 → Dec 2027 expected thyroid tumor Fujian Medical University Not yet recruiting No outcome recorded
Phase 4 NCT06931808 Mar 2025 → Mar 2026 overdue rectum adenocarcinoma First Affiliated Hospital of Ningbo University Enrolling by invitation No outcome recorded
Phase 4 NCT06499610 Jul 2024 → Oct 2027 expected gastric cancer First Affiliated Hospital Xi'an Jiaotong University Not yet recruiting No outcome recorded
Phase 4 NCT05843292 Jul 2023 → Dec 2024 overdue triple-negative breast carcinoma Shanghai Jiao Tong University School of Medicine Not yet recruiting No outcome recorded
Phase not applicable30 trials · 1 missed
— NCT07859410 Oct 2026 → Oct 2028 expected gastroesophageal junction adenocarcinoma Anhui Medical University Not yet recruiting No outcome recorded
— NCT07809165 Sep 2026 → Sep 2029 expected chronic hepatitis B virus infection Beijing 302 Hospital Not yet recruiting No outcome recorded
— NCT07542912 Jun 2026 → Jun 2029 expected — Sun Yat-sen University Not yet recruiting No outcome recorded
— NCT07350824 Dec 2025 → Dec 2027 expected hepatocellular carcinoma Tongji Hospital Not yet recruiting No outcome recorded
— NCT07474103 Nov 2025 → Mar 2028 expected rectum adenocarcinoma Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Recruiting No outcome recorded
— NCT07077798 Aug 2025 → Aug 2026 overdue hepatocellular carcinoma Wan-Guang Zhang Not yet recruiting No outcome recorded
— NCT07067450 Jul 2025 → Dec 2026 expected esophageal squamous cell carcinoma Sichuan University Not yet recruiting No outcome recorded
— NCT06740370 Dec 2024 → Dec 2025 overdue hepatocellular carcinoma Sun Yat-sen University Recruiting No outcome recorded
— NCT06622031 Oct 2024 → Dec 2026 expected hepatocellular carcinoma, portal vein thrombosis Sun Yat-sen University Recruiting No outcome recorded
— NCT06549855 Oct 2024 → Jul 2029 expected endometrial cancer, endometrioid adenocarcinoma Peking University People's Hospital Not yet recruiting No outcome recorded
Comparator or background therapy90 trials
Phase 0 NCT06347198 Background Apr → Dec 2024 colorectal cancer Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Unknown No outcome recorded
Phase 1 NCT07557251 Background Aug 2026 → Dec 2028 expected hepatocellular carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting No outcome recorded
Phase 1 NCT07699757 Background Jul 2026 → Apr 2029 expected non-small cell lung carcinoma, pancreatic ductal adenocarcinoma Haisco Pharmaceutical Group Co., Ltd. Not yet recruiting No outcome recorded
Phase 1 NCT06896422 Background Jun 2025 → Dec 2026 expected non-small cell lung carcinoma The First Affiliated Hospital of Zhengzhou University Recruiting No outcome recorded
Phase 1 NCT06773312 Background Feb 2025 → Oct 2026 expected gastroesophageal junction adenocarcinoma Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. Recruiting No outcome recorded

Press releases naming this drug 115 releases

DateIssuerRelease
2026-05-21 Hutchison Medipharma Limited HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma hutch-med.com ↗
2026-05-21 Innovent Biologics (Suzhou) Co. Ltd. Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma innoventbio.com ↗
2025-12-07 Innovent Biologics (Suzhou) Co. Ltd. Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List innoventbio.com ↗
2025-06-05 Hutchison Medipharma Limited HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma hutch-med.com ↗
2025-06-05 Innovent Biologics (Suzhou) Co. Ltd. Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma innoventbio.com ↗
2025-04-29 Innovent Biologics (Suzhou) Co. Ltd. Innovent and ImmVirX Expand Collaboration to Investigate TYVYT® with IVX037 in Liver Cancer innoventbio.com ↗
2025-04-28 ImmVirx Pty Ltd ImmVirX and Innovent Expand Collaboration to Investigate IVX037 with TYVYT® in Liver Cancer immvirx.com ↗
2025-03-19 Hutchison Medipharma Limited HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China hutch-med.com ↗
2025-03-19 Innovent Biologics (Suzhou) Co. Ltd. Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China innoventbio.com ↗
2025-02-24 Innovent Biologics (Suzhou) Co. Ltd. NMPA Accepts NDA and Grants Priority Review Designation to Innovent’s Ipilimumab Injection, China’s First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer innoventbio.com ↗
2024-12-26 Mankind Pharma Limited Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab mankindpharma.com ↗
2024-12-04 Innovent Biologics (Suzhou) Co. Ltd. Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer innoventbio.com ↗
Show all 115 releases opens the full record — a long page

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 664 sources stand behind the page.

FieldValueCited text
Known as Sintilimab “Drug sensitivity testing will be performed on a panel of approved targeted and immunotherapeutic agents (including Apatinib, Atezolizumab + Bevacizumab, Donafenib +...” NCT07363356 ↗
645

“Once stable disease is confirmed by two consecutive radiological assessments, sintilimab (200 mg intravenously every three weeks) is added as maintenance treatment until...” NCT07637448 ↗

“Sintilimab 200mg+ Bevacizumab 7.5mg/kg+Oxaliplatin 130mg/m2+Capecitabine 1250mg/m2 for 6-8cycles, Sintilimab 200mg+ Bevacizumab 7.5mg/kg+Capecitabine 1250mg/m2 as maintenance...” NCT06973343 ↗

“Patients receive 3 cycles of preoperative chemotherapy with Sintilimab（PD-1 inbibitor） and SOX (every 3 weeks), followed by radiotherapy (total dose of 36-40Gy in 18-22...” NCT06250894 ↗

“Our prior findings demonstrated that the combination of autologous NK cells with the PD-1 antibody (Sintilimab), offered promising efficacy in NSCLC patients who failed the...” PMID 40469279 ↗ May 2025

“The patients in the postoperative adjuvant treatment cohort received regular PD-1 inhibitor adjuvant therapy (Sintilimab), once every 21 days, for a total of 8 times, and...” NCT07350824 ↗

“Fixed Delay Arm Delayed PD-1 + Chemo PD-1 inhibitor (e.g., Sintilimab/Keytruda/Tislelizumab/Camrelizumab/Toripalimab/Nivolumab/Atezolizumab/Sugemalimab) Immune checkpoint...” NCT07190027 ↗

“The purpose of this study was to evaluate the effect of capecitabine-based long-term radiotherapy followed by 3 cycles Sintilimab (PD-1 inhibitor) in patients with locally...” NCT06493240 ↗

“Sintilimab 200 mg intravenously on day 1, pegaspargase 2500 IU/m² on day 1 with a maximum single dose of 3750 IU, and anlotinib 8 mg orally on days 1-14, repeated every 21 days...” NCT07678229 ↗

“Patients with squamous cell carcinoma received docetaxel administered in 3-week cycles, and patients with adenocarcinoma received pemetrexed, patinum and one of sintilimab or...” NCT07076693 ↗

“The commonly used anti-PD-1 mAb usages are as follows: Nivolumab, 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Sintilimab, 200mg solution intravenously once...” NCT06728657 ↗

Show 635 more sources
Known as Darbersol “fixed dose of either terriplizumab injection (Toripalimab) or Sintilimab injection (Darbersol, Sintilimab).” NCT06078670 ↗
Known as IBI308 “CONSIST: A Phase III Randomized Control Study of Consolidation Sintilimab (IBI308) After Concurrent Chemoradiation Versus Chemoradiation Alone in Patients With Unresectable...” NCT03884192 ↗
23

“whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).” NCT06584032 ↗

“Participants receive Sintilimab(IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle” NCT03765775 ↗

“Sintilimab (R&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody.” NCT05171660 ↗

“Sintilimab injection (IBI308) as neoadjuvant therapy in patients with resectable NSCLC” NCT04371796 ↗

“Sintilimab (IBI308) is a monoclonal antibody targeting programmed death-1 (PD-1).” NCT04089657 ↗

“IBI308: 200mg on day1 of each cycle, 3 cycles” NCT04833387 ↗

“Humanized PD-1 antibody (Sintilimab, IBI308)” NCT04194359 ↗

“Sintilimab (IBI308) 200mg IV Q3W” NCT03228836 ↗

“IBI308 IV 200mg Q3W Day1” NCT05164458 ↗

“IBI308 200mg/3 weeks” NCT03114683 ↗

Show 13 more sources
Known as Sin “OBJECTIVES: ORIENT-16, a phase III clinical trial conducted at 62 hospitals in China, reported that add-on sintilimab (Sin) to chemotherapy (Chemo) had favorable efficacy...” PMID 38594905 ↗ Apr 2024
Known as Sindilizumab “Sindilizumab (Sintilimab) is a humanized anti-PD-1 monoclonal antibody” NCT06620822 ↗
Known as Sintilimab (IBI308) “Sintilimab (IBI308)” NCT05572463 ↗
Known as Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel ClinicalTrials.gov intervention name — accepted as the source's own label NCT06454435 ↗
Known as Sintilimab Injection “200mg PD-L1 antibody(Sintilimab Injection) will be given on D14, 1 hour after NK cells infusion.” NCT03958097 ↗
2

“Sintilimab Injection” NCT07319429 ↗

“Sintilimab injection” NCT05809336 ↗
Known as Tyvyt “This is a single-arm, open-label Phase IIa study designed to evaluate the efficacy, safety, and PK of CVM-1118 in combination with Sintilimab (Tyvyt ®) and TACE in participants...” NCT07521852 ↗
2

“CIT (chemoimmunotherapy): anti-PD-1 sintilimab (Tyvyt) 200 mg IV on Day 1 q3w combined with platinum-based doublet chemotherapy” NCT04702009 ↗

“Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.” NCT05648487 ↗
Action Inhibit “This study (ORIENT-4) aimed to assess the efficacy and safety of sintilimab, a humanized anti-PD-1 antibody, in patients with relapsed/refractory extranodal NK/T cell lymphoma...” PMID 34702811 ↗ Oct 2021
Modality Monoclonal antibody “Neoadjuvant Sintilimab (PD-1 Antibody)-Chemotherapy” NCT03619824 ↗
Route Intravenous “Participants will receive IBI308 1mg/kg, 3mg/kg or 10mg/kg intravenous every 2 weeks, or 200mg intravenous every 3 weeks” NCT02937116 ↗
Target PDCD1 “anti-programmed death 1 antibody” PMID 32781263 ↗ Aug 2020